Transcode Therapeutics, Inc. 8-K/A

What Happened

• Transcode Therapeutics, Inc. (RNAZ) announced it received a Nasdaq Listing Qualifications deficiency letter stating it does not meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. The Company reported stockholders’ equity of $1,251,427 as of March 31, 2026.
• Nasdaq has given the Company 45 calendar days (until July 3, 2026) to submit a plan to regain compliance. The Company plans to base its Compliance Plan on obtaining stockholder approval to convert Series A Non‑Voting Convertible Preferred Stock into common stock (a preliminary proxy was filed May 8, 2026). If approved, the Series A Preferred would be reclassified from temporary equity to equity and the Company expects to regain compliance.
• The Nasdaq staff may grant a further 180‑day extension to regain compliance. If the staff rejects the plan or the Company fails to cure the deficiency, a delisting determination could follow; the Company may request a hearing to stay any delisting action.

Key Details

• Reported stockholders’ equity: $1,251,427 (as of March 31, 2026).
• Nasdaq minimum required equity (Rule 5550(b)(1)): $2,500,000.
• Compliance plan submission deadline: July 3, 2026 (45 days from the notice).
• Preliminary proxy to seek conversion approvals filed: May 8, 2026; if conversion vote not obtained by Dec 31, 2026, Series A holders may elect a redemption feature (hence current temporary equity classification).

Why It Matters

• Failure to regain compliance could lead to delisting from Nasdaq, which would likely reduce liquidity, hurt the company’s reputation and could materially lower the value of shareholders’ holdings.
• The most direct path to compliance described by the Company is shareholder approval of preferred‑stock conversion; outcomes depend on the proxy vote, Nasdaq’s acceptance of the Compliance Plan, and any extension granted.
• There are no guarantees the Company will regain compliance; investors should monitor proxy filings, the upcoming stockholder meeting, and any Nasdaq correspondence or hearing outcomes.